Retrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20 years

  • Fergün YılmazEmail author
  • Dilan Atilla
  • Nagihan Akkaş
  • Hale Bülbül
  • Nur Soyer
  • Derya Demir
  • Demet Kiper
  • Aylin Avcı
  • Filiz Vural
  • Güray Saydam
  • Fahri Şahin
  • Mine Hekimgil
  • Nazan Özsan
  • Raika Durusoy
  • Bahriye Payzın
Original Article


We aimed to analyze the characteristics and response rates of different treatment modalities in hairy cell leukemia patients over 20 diagnosed as hairy cell leukemia (HCL). Clinical data, response rates and survival outcome of the patients who were diagnosed with HCL were retrospectively analyzed. Fifty-two patients with a median age of 50 (28–87) years were enrolled in the study. 38 patients (73%) were male and male to female ratio was 2.7. First line therapy was cladrabine in 36 patients (69.2%). The overall response rate was 97%. CR and PR rates were 86.1% and 11.1%, respectively. Interferon was used in 10(19.2%) patients who were diagnosed before 2000s years. CR and PR rates were 70% and 30%, respectively. Although the CR rates were lower in IFN group, this difference could not be reached statistically significance (p = 0.24). The median follow up was 48 months (12–252). The median OS was not reached and median PFS was 150 months (95% CI, 116–214). The OS at 36 and 48 months were 95.9% and 92.3%, respectively and the PFS at 36 and 48 months were 90.2% and 83.4%, respectively. After the introduction of purine analogues, the fate of the HCL patients have been changed. Cladrabin achieved very high response rates in both young and older patients, in our study. Although relapse still constitutes a problem, another single dose of cladrabine results in good response rates.


Hairy cell leukemia Cladrabin Treatment Survival rates Response rates 


Compliance with Ethical Standards

Conflict of interest

Authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from all participants included in the study.


  1. 1.
    Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677–683CrossRefGoogle Scholar
  2. 2.
    Bernstein L, Newton P, Ross RK (1990) Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 50(12):3605–3609PubMedGoogle Scholar
  3. 3.
    Quest GR, Johnton JB (2015) Clinical features and diagnosis of hairy cell leukemia. Best Pract Res Clin Haematol 28(4):180–192CrossRefGoogle Scholar
  4. 4.
    Flandrin G, Sigaux F, Sebahoun G, Bouffette P (1984) Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 11(4 Suppl 2):458–471PubMedGoogle Scholar
  5. 5.
    Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D (2012) British Committee for Standards in Haematology. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156(2):186–195CrossRefGoogle Scholar
  6. 6.
    Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R et al (2004) Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 363(9424):1869–1870CrossRefGoogle Scholar
  7. 7.
    Grever MR, Lozanski G (2011) Modern strategies for hairy cell leukemia. J Clin Oncol 29(5):583–590CrossRefGoogle Scholar
  8. 8.
    Grever MR (2010) How I treat hairy cell leukemia. Blood 115(1):21–28CrossRefGoogle Scholar
  9. 9.
    Golomb HM, Vardiman JW (1983) Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61(2):349–352CrossRefGoogle Scholar
  10. 10.
    Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman JU (1986) Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 68(2):493–497CrossRefGoogle Scholar
  11. 11.
    Saven A, Burian C, Koziol JA, Piro LD (1998) Longterm follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6):1918–1926CrossRefGoogle Scholar
  12. 12.
    Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R et al (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96(9):2981–2986PubMedGoogle Scholar
  13. 13.
    Foucar KFB, Catovsky D, Stein H (2008) Hairy cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of the haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, pp 188–190Google Scholar
  14. 14.
    Thompson PA, Ravandi F (2017) How I manage patients with hairy cell leukaemia. Br J Haematol 177(4):543–556CrossRefGoogle Scholar
  15. 15.
    Anonymous. (1987) Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia 1:405Google Scholar
  16. 16.
    Hacioglu S, Bilen Y, Eser A, Sivgin S, Gurkan E, Yildirim R, Aydogdu I, Dogu MH, Yilmaz M, Kayikci O, Tombak A, Kuku I, Celebi H, Akay MO, Esen R, Korkmaz S, Keskin A (2015) Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy. Hematol Oncol. 33(4):192–198CrossRefGoogle Scholar
  17. 17.
    Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, Rai K, Tallman MS (2016) Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol 175(3):402–409. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gupta AK, Sachdeva MU, Ahluwalia J, Das R, Naseem S, Sharma P, Kumar N, Malhotra P, Varma N, Varma S (2015) Haematological profile of 21 patients with hairy cell leukaemia in a tertiary care centre of north India. Indian J Med Res. 142(4):426–429. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Payandeh M, Sadeghi M, Sadeghi E (2015) Hairy cell leukemia: a retrospective study on 11 patients in the Western of Iran. Int J Hematol Oncol Stem Cell Res. 9(3):133–137PubMedPubMedCentralGoogle Scholar
  20. 20.
    Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT (2017) Long-term outcomes of hairy cell leukemia treated with purine analogs: a comparison with the general population. Clin Lymphoma Myeloma Leuk 17(12):857–862CrossRefGoogle Scholar
  21. 21.
    Erkut N, Batur D, Akıdan O, Karabacak V, Sonmez M (2018) Long term treatment outcome of patients with hairy cell leukemia: single center experience. J Med Sci 38(3):236–240Google Scholar
  22. 22.
    Rosenberg JD, Burian C, Waalen J, Saven A (2014) Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 123(2):177–183CrossRefGoogle Scholar
  23. 23.
    Inbar M, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Najib D, Rouvio O, Shaulov A, Greenbaum U, Polliack A, Tadmor T (2018) Hairy cell leukemia: retrospective analysis of demographic data and outcome of 203 patients from 12 medical centers in Israel. Anticancer Res. 38(11):6423–6429CrossRefGoogle Scholar
  24. 24.
    Öngören Ş, Eşkazan AE, Berk S, Elverdi T, Salihoğlu A, Ar MC, Başlar Z, Aydın Y, Tüzüner N, Soysal T (2017) Retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience. Turk J Haematol 34(4):291–299CrossRefGoogle Scholar
  25. 25.
    Andrasiak I, Rybka J, Wrobel T (2018) Response to the therapy in hairy cell leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 18(6):392–399.e3CrossRefGoogle Scholar
  26. 26.
    Goodman GR, Burian C, Koziol JA, Saven A (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21(5):891–896CrossRefGoogle Scholar
  27. 27.
    Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS (2005) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106(1):241–246CrossRefGoogle Scholar
  28. 28.
    Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18(9):1476–1481CrossRefGoogle Scholar
  29. 29.
    Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 17(1):45–51CrossRefGoogle Scholar
  30. 30.
    Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13(4):974–982CrossRefGoogle Scholar
  31. 31.
    Legrand O, Vekhoff A, Marie JP, Zittoun R, Delmer A (1997) Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects. Br J Haematol 99(1):165–167CrossRefGoogle Scholar
  32. 32.
    Hoffman MA, Janson D, Rose E, Rai KR (1997) Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15(3):1138–1142CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  • Fergün Yılmaz
    • 1
    Email author
  • Dilan Atilla
    • 2
  • Nagihan Akkaş
    • 3
  • Hale Bülbül
    • 2
  • Nur Soyer
    • 2
  • Derya Demir
    • 4
  • Demet Kiper
    • 3
  • Aylin Avcı
    • 5
  • Filiz Vural
    • 2
  • Güray Saydam
    • 2
  • Fahri Şahin
    • 2
  • Mine Hekimgil
    • 4
  • Nazan Özsan
    • 4
  • Raika Durusoy
    • 6
  • Bahriye Payzın
    • 3
  1. 1.Department of Hematology, Internal MedicineMarmara UniversityIstanbulTurkey
  2. 2.Department of Hematology, Internal MedicineEge UniversityIzmirTurkey
  3. 3.İnternal Medicine, Department of Hematologyİzmir Katip Celebi UniversityIzmirTurkey
  4. 4.Department of PathologyEge UniversityIzmirTurkey
  5. 5.Department of Pathologyİzmir Katip Celebi UniversityIzmirTurkey
  6. 6.Department of Public HeathEge UniversityIzmirTurkey

Personalised recommendations